Floatz logo

TAK228

Ovarian Clear Cell Adenocarcinoma

Imperial College LondonPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Ovarian Clear Cell Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
NRG Oncology
Phase 3BBB
Olaparib
National Cancer Institute (NCI)
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB

View all 41 →

Same molecule, other indications

TAK228 is also rated in:

ovarian carcinosarcomaDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian serous adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →